Literature DB >> 6679629

Is isoniazid-hepatotoxicity induced by the metabolite, hydrazine?

A Noda, K Y Hsu, H Noda, Y Yamamoto, T Kurozumi.   

Abstract

The effects of rifampicin (RMP) on isoniazid (INH) metabolism in rabbits were examined from the viewpoint of extensive hepatitis. After the RMP pretreatment, no remarkable changes were observed in the plasma levels of INH as well as its metabolites, acetylisoniazid (AcINH), acetylhydrazine (AcHz) and diacetylhydrazine (DAcHz) with the exception of hydrazine (Hz). After an oral administration of INH or Hz hydrate, the stochastic examination showed that the AUC0-8hr values of Hz plasma levels in RMP pretreated groups were significantly less than those in the control rabbits. RMP treatment was also shown to induce rabbit liver cytochrome P-450 activity. Histological studies demonstrated that Hz causes more remarkable hepatic necrosis in rabbits pretreated with RMP than in the control rabbits. These observations could suggest that Hz is a key intermediate of INH-hepatitis through the transformation of some hepatotoxic species by microsomal oxidation that is facilitated by RMP.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6679629     DOI: 10.7888/juoeh.5.183

Source DB:  PubMed          Journal:  J UOEH        ISSN: 0387-821X


  10 in total

Review 1.  A guide to the management of tuberculosis in patients with chronic liver disease.

Authors:  Radha K Dhiman; Vivek A Saraswat; Harshal Rajekar; Chandrasekhar Reddy; Yogesh K Chawla
Journal:  J Clin Exp Hepatol       Date:  2012-09-21

2.  Increased urinary excretion of toxic hydrazino metabolites of isoniazid by slow acetylators. Effect of a slow-release preparation of isoniazid.

Authors:  E Peretti; G Karlaganis; B H Lauterburg
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

Review 3.  Animal models of hepatotoxicity.

Authors:  Ganesh Singh Bhakuni; Onkar Bedi; Jitender Bariwal; Rahul Deshmukh; Puneet Kumar
Journal:  Inflamm Res       Date:  2015-10-01       Impact factor: 4.575

4.  Lack of liver injury in Wistar rats treated with the combination of isoniazid and rifampicin.

Authors:  Imir G Metushi; Jack Uetrecht
Journal:  Mol Cell Biochem       Date:  2013-10-23       Impact factor: 3.396

Review 5.  Hepatotoxic effects of therapies for tuberculosis.

Authors:  Bahaa E Senousy; Sanaa I Belal; Peter V Draganov
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2010-08-31       Impact factor: 46.802

6.  NAT2 6A, a haplotype of the N-acetyltransferase 2 gene, is an important biomarker for risk of anti-tuberculosis drug-induced hepatotoxicity in Japanese patients with tuberculosis.

Authors:  Norihide Higuchi; Naoko Tahara; Katsunori Yanagihara; Kiyoyasu Fukushima; Naofumi Suyama; Yuichi Inoue; Yoshitsugu Miyazaki; Tsutomu Kobayashi; Kohichiro Yoshiura; Norio Niikawa; Chun-Yang Wen; Hajime Isomoto; Saburou Shikuwa; Katsuhisa Omagari; Yohei Mizuta; Shigeru Kohno; Kazuhiro Tsukamoto
Journal:  World J Gastroenterol       Date:  2007-12-07       Impact factor: 5.742

7.  Factors in hydrazine formation from isoniazid by paediatric and adult tuberculosis patients.

Authors:  W L Gent; H I Seifart; D P Parkin; P R Donald; J H Lamprecht
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

8.  Direct oxidation and covalent binding of isoniazid to rodent liver and human hepatic microsomes: humans are more like mice than rats.

Authors:  Imir G Metushi; Tetsuya Nakagawa; Jack Uetrecht
Journal:  Chem Res Toxicol       Date:  2012-10-16       Impact factor: 3.739

9.  Antituberculosis Drug-Induced Hepatotoxicity in IranianTuberculosis Patients: Role of Isoniazid Metabolic Polymorphism.

Authors:  Mohammad Sistanizad; Ebrahim Azizi; Hosein Khalili; Mahboobeh Hajiabdolbaghi; Kheirollah Gholami; Reza Mahjub
Journal:  Iran J Pharm Res       Date:  2011       Impact factor: 1.696

10.  Effectiveness of hepatoprotective drugs for anti-tuberculosis drug-induced hepatotoxicity: a retrospective analysis.

Authors:  Zenya Saito; Yugo Kaneko; Akira Kinoshita; Yusuke Kurita; Kyuto Odashima; Tsugumi Horikiri; Yutaka Yoshii; Aya Seki; Yoshitaka Seki; Hiroshi Takeda; Kazuyoshi Kuwano
Journal:  BMC Infect Dis       Date:  2016-11-11       Impact factor: 3.090

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.